[Inhibiting the pro-tumor and transcription factor FACT: Mechanisms]

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer stem cells (CSCs) contribute to treatment resistance and poor clinical outcomes.
• Conventional therapies often fail to eradicate CSCs, highlighting the need for novel therapeutic strategies.
• CSCs are characterized by slow metabolism and high resistance to existing treatments.

Purpose of the Study:

• To investigate the efficacy of curaxins, a novel class of compounds, against cancer stem cells (CSCs).
• To evaluate the impact of curaxins on key molecular pathways involved in tumor progression and CSC survival.
• To assess the potential of curaxins as a new therapeutic approach for overcoming treatment resistance in cancer.

Main Methods:

• In vitro and in vivo studies were conducted to assess curaxin activity.
• Analysis of curaxin's effects on key molecular pathways including p53, NF-κB, and HSF1.
• Evaluation of curaxin's impact on CSC populations in preclinical cancer models.

Main Results:

• Curaxins simultaneously target multiple oncogenic molecular cascades (p53, NF-κB, HSF1).
• Curaxins inhibit genes involved in matrix metalloproteinases, PI3K/AKT/mTOR signaling, and oncogenes like c-MYC.
• Treatment with curaxin CBL0137 reduced CSC population, contrasting with gemcitabine monotherapy which increased it.

Conclusions:

• Curaxins demonstrate broad-spectrum antitumor activity by targeting multiple cancer-related pathways.
• Curaxins effectively reduce cancer stem cell populations, suggesting potential to overcome treatment resistance.
• Curaxins, particularly FACT inhibitors, represent a promising new class of anticancer drugs with multi-targeted effects.